Leqembi Approval Opens Door To Alzheimer’s Market For Lilly And Others

Pointers On Competition Expected From Lilly’s Full Phase III Data

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.